Johnson and Johnson's experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency's human medicines committee (CHMP) at its May meeting.
The new Ebola vaccine consists of two components, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo). Zabdeno is given first and Mvabea is administered approximately eight weeks later as a booster.